Applications of Rufloxacin Hydrochloride in Industrial Manufacturing

Our Rufloxacin Hydrochloride serves as a high-purity pharmaceutical intermediate used by regulated manufacturers across various controlled environments. We support downstream producers by maintaining strict QA/QC procedures during synthesis and guaranteeing batch-to-batch consistency. The following application scenarios highlight the core industrial uses for Rufloxacin Hydrochloride, including sector-specific technical integration and regulatory adherence.

1. Veterinary Injectable Antibacterial Preparations

Veterinary drug manufacturers use Rufloxacin Hydrochloride as an active pharmaceutical ingredient (API) in injectable antibacterial treatments for livestock and companion animals. Integration of the API occurs during aseptic formulation, requiring stringent in-process controls to ensure therapeutic consistency and regulatory traceability for parenteral veterinary products. Accuracy in dosage and compliance with pharmacopoeial standards underpin market acceptance for broad-spectrum veterinary products.

Industry compliance standards

• China Veterinary Pharmacopoeia (ChVP)
• European Pharmacopoeia (Ph. Eur.) injectable requirements for veterinary drugs
• Good Manufacturing Practice for Veterinary Medicinal Products (GMP-Vet)
• ISO 9001:2015 for pharmaceutical quality management

Typical usage ratio

• 50–100 mg per 10 mL injection; formulation varies by animal species and targeted pathogen, adjusted according to pharmacological dosing studies and veterinary labeling requirements.

Downstream process integration

• API enters at the sterile solution compounding stage, followed by filtration, aseptic filling, and terminal sterilization.

Final product types

• Bovine injectable antibiotics
• Companion animal antibacterial injectables
• Poultry disease management solutions

2. Aquaculture Oral Dosage Formulations

Downstream aquaculture pharmaceutical plants use Rufloxacin Hydrochloride to prepare oral tablet and powder premixes designed for fish and shrimp farming. Manufacturers must respect environmental and food chain safety limits, blending the material into feed premixes under controlled batch blending and granulation processes. Stringent sampling plans and HACCP principles remain in place due to the potential for residue carryover into aquaculture products.

Industry compliance standards

• China Feed Additive Approval Catalogue
• EU Regulation (EC) No 1831/2003 on feed additives
• Aquaculture drug residue monitoring requirements under FAO/WHO Codex Alimentarius
• Local Department of Fisheries product registration

Typical usage ratio

• 10–30 mg/kg in final feed, with precise adjustment based on fish/shrimp species, age group, and pathogen profile; maximal usage determined by approved veterinary maximum residue limits (MRLs).

Downstream process integration

• Material incorporated during dry blending before pelletization or premix granulation, with uniformity assured via in-line mixing controls and periodic QC sampling of homogenized batches.

Final product types

• Medicated fish feed tablets
• Shrimp feed antimicrobial powders
• Oral antibiotic premix sachets for aquaculture

3. Pharmaceutical Intermediate for Human API Synthesis

Bulk drug manufacturers utilize Rufloxacin Hydrochloride as a starting intermediate or key building block during the multi-step chemical synthesis of advanced human-use APIs. Full traceability and reprocessing logs support GMP documentation, ensuring that the raw material fits stringent purity control limits imposed by finished API regulatory filings. Integration occurs at the stage requiring the fluoroquinolone core structure in the synthetic route.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• US FDA cGMP for Bulk Pharmaceutical Chemicals (21 CFR Part 210/211)
• European Pharmacopoeia monograph for starting materials
• DMF (Drug Master File) suitability for regulatory filings

Typical usage ratio

• Input precisely calculated per chemical reaction stoichiometry; adjustment based on target synthesis yield and purity specification. Typical charge is 1.0–1.2 equivalents relative to follow-on intermediates, depending on process optimization findings.

Downstream process integration

• Material introduced at the designated intermediate step—most commonly during condensation reactions for assembly of the fluoroquinolone core; followed by purification, crystallization, and analytical QC confirmation.

Final product types

• Advanced pharmaceutical ingredients (e.g., quinolone classes)
• Human-use injectable antibiotics
• Oral dosage form actives utilizing fluoroquinolone motifs

4. In-vitro Diagnostic (IVD) Reagent Manufacturing

Specialty diagnostic reagent manufacturers incorporate Rufloxacin Hydrochloride as a specific reference compound or calibration standard within microbiological and antimicrobial sensitivity testing kits. Production teams blend and dissolve the compound in pre-measured fractions to calibrate assay plates or culture media, relying on validated preparation protocols to meet international sensitivity test guidelines.

Industry compliance standards

• ISO 13485:2016 Medical Device – Quality Management Systems
• CLSI M07 and M100 Antimicrobial Susceptibility Testing Standards
• IVD Directive 98/79/EC (replaced by IVDR 2017/746 in EU)
• US FDA 21 CFR Part 820 — Quality System Regulation for IVDs

Typical usage ratio

• 0.5–5 µg per disc or 0.1–10 mg/L in agar, strictly determined by the sensitivity range stated in CLSI calibration protocols for reference materials; batch blending follows validated master formulas.

Downstream process integration

• Material dissolved or suspended during microbiological media or disc preparation; integration monitored through in-process titer testing and end-product stability verification before packaging.

Final product types

• Antibacterial susceptibility test discs
• Diagnostic agar plates for clinical microbiology
• Reference standard reagent kits for laboratory quality control